Seres Therapeutics (MCRB) Net Margin (2016 - 2026)

Seres Therapeutics (MCRB) posted Net Margin of 7140.78% for Q1 2026, down 138149.65% sequentially from 5.17% in Q4 2023.

Seres Therapeutics (MCRB) Net Margin (2016 - 2026) Analysis & Trends

Seres Therapeutics has reported Net Margin for 9 years, with the latest figure at 7140.78% in Q1 2026.

Quarterly Net Margin changed N/A year-over-year to 7140.78% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2228.77% (changed N/A YoY) and the FY2022 annual result came in at 3509.5%, down 346391.0% from the prior year.
Net Margin retreated to 7140.78% in Q1 2026 per MCRB's latest filing, from 5.17% in the prior quarter.
Over five years, Net Margin peaked at 36.81% in Q2 2023 and troughed at 478313.21% in Q3 2022.
A 3-year average of 65249.25% and a median of 6188.62% in 2022 frame the typical range for Net Margin.
The sharpest annual moves came in 2022 and 2023: Net Margin tumbled 46268038 bps in 2022, then surged 47610708 bps in 2023.
Over 3 years, Net Margin stood at 6188.62% in 2022, then soared by 100 bps to 5.17% in 2023, then sank by 138150 bps to 7140.78% in 2026.
According to Business Quant data, Net Margin over the past three periods registered 7140.78%, 5.17%, and 2206.13% for Q1 2026, Q4 2023, and Q3 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	139.81 Bn	131.96 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	86.56 Bn	78.56 Bn	3.93 Bn	30.23%
3	Argenx Se	65.72 Bn	60.53 Bn	1.37 Bn	31.16%
4	Moderna	58.75 Bn	53.61 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	31.76 Bn	28.45 Bn	992.69 Mn	12.74%
7	BioNTech SE	28.59 Bn	10.19 Bn	668.28 Mn	-16.51%
8	Insmed	27.63 Bn	26.47 Bn	358.27 Mn	-3.12%
9	Royalty Pharma	27.24 Bn	26.40 Bn	-	12.09%
10	Seres Therapeutics	44.36 Mn	44.36 Mn	-	-2,865.76%

Download Data